Cellosaurus logo
expasy logo

Cellosaurus 21M18 (CVCL_A4BK)

[Text version]
Cell line name 21M18
Accession CVCL_A4BK
Resource Identification Initiative To cite this cell line use: 21M18 (RRID:CVCL_A4BK)
Comments Group: Patented cell line.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8670.
Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized demcizumab (OMP-21M18) therapeutic antibody.
Monoclonal antibody isotype: Not specified.
Monoclonal antibody target: UniProtKB; Q9NR61; Human DLL4.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Category Hybridoma
Publications

PubMed=19664991; DOI=10.1016/j.stem.2009.05.019
Hoey T., Yen W.-C., Axelrod F.T., Basi J., Donigian L., Dylla S.J., Fitch-Bruhns M., Lazetic S., Park I.-K., Sato A., Satyal S., Wang X.-H., Clarke M.F., Lewicki J., Gurney A.L.
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Cell Stem Cell 5:168-177(2009)

Patent=US9376497
Gurney A.L., Axelrod F.T., Hoey T., Satyal S.
Compositions and methods for diagnosing and treating cancer.
Patent number US9376497, 28-Jun-2016

Cross-references
Cell line collections (Providers) ATCC; PTA-8670
Encyclopedic resources Wikidata; Q105505888
Entry history
Entry creation12-Jan-2021
Last entry update21-Mar-2023
Version number5